6 Top Gainers In Healthcare Sector (RMED, BCEL, TROV…)

(RTTNews) - The following are some of today's top gainers in the pharma/biotech sector.

1. Ra Medical Systems Inc. (RMED)

Ra Medical is a commercial-stage medical device company, with a focus on vascular and dermatological diseases.

Gained 32.43% to close Thursday's (Aug.15) trading at $1.96.

News: No news

Recent event:

On August 13, 2019, the Company reported certain preliminary financial results for the quarter ended June 30, 2019, as well as a leadership transition.

Ra Medical expects revenue to be between $2.02 million and $2.2 million for the second quarter of 2019.

The Company also announced the termination of Dean Irwin from the posts of Chief Executive Officer, Co-President, and Chief Technology Officer, and as Chairman of its Board of Directors. Andrew Jackson, currently serving as Chief Financial Officer, has been appointed to serve as Interim Chief Executive Officer.

There is also going to be a delay in the reporting of earnings for the second quarter of 2019 and the filing of its Quarterly Report on Form 10-Q for the quarter ended June 30, 2019.

2. Sintx Technologies Inc. (SINT)

SINTX Technologies is a commercial biomaterial company focused on using its silicon nitride technology platform to develop, manufacture and sell a broad range of medical devices.

Gained 23.73% to close Thursday's trading at $2.19.

News: The Company announced financial results for the second quarter ended June 30, 2019, and also revealed that it is now compliant with the minimum bid price requirement for continued listing on the Nasdaq Stock Market.

The revenue for the second quarter of 2019 was $0.2 million compared to nil revenue in the year-ago quarter. The loss from continuing operations for the recent second quarter was $0.73 million or $1.46 per share compared to a loss from continuing operations $2.181 million or $12.06 per share in the year-ago quarter.

As of June 30, 2019, the Company had cash and cash equivalents of $3.2 million.

3. Entera Bio Ltd. (ENTX)

Entera Bio is a clinical-stage biopharmaceutical company focused on developing orally-delivered large molecule therapeutics for use in orphan indications and other areas with significant unmet medical needs.

Gained 23.22% to close Thursday's trading at $2.60.

News: No news

Near-term Catalyst:

The Company is scheduled to report financial results for the second quarter ended June 30, 2019, and provide a corporate update on August 20, 2019.

Clinical Trials & Near-term Catalysts:

-- A phase II clinical trial of Oral PTH 1-34 for hypoparathyroidism is underway. The Company reported positive results from Part I of this study last November. Part 1 of the phase II trial in patients with hypoparathyroidism was designed to evaluate the PK and PD profiles of Oral PTH (1-34) and injectable PTH (1-84), Natpara. -- A phase II study of osteoporosis drug candidate EB613 was initiated as recently as July 2, 2019.

4. Atreca Inc. (BCEL)

Atreca Inc. is a biopharmaceutical company developing novel antibody-based immunotherapeutics to treat a range of solid tumor types.

Gained 19.97% to close Thursday's trading at $16.10.

News: No news

Recent event:

The Company went public on the Nasdaq Global Select Market on June 20, 2019, offering its shares at a price of $17.00 per share.

Pipeline and Near-term Catalysts:

The Company's lead product candidate is ATRC-101, a monoclonal antibody in preclinical development that has demonstrated reactivity with ovarian, non-small cell lung, colorectal and breast cancer samples from multiple patients.

The Company expects to file an IND application for ATRC-101 in late 2019 and initiate a phase 1b clinical trial in patients with solid tumors in early 2020, subject to FDA approval of IND application.

5. TrovaGene Inc. (TROV)

Trovagene is a clinical-stage oncology therapeutics company.

Gained 14.79% to close Thursday's trading at $1.63.

News: The Company announced that new clinical data from its phase II trial of Onvansertib, in combination with Zytiga, in metastatic Castration-Resistant Prostate Cancer, will be presented on August 24, 2019.

Clinical Trials:

The Company's lead product candidate is Onvansertib being tested:

-- in combination with either low-dose cytarabine (LDAC) or decitabine for the treatment of Acute Myeloid Leukemia (AML) under a phase Ib/II trial. -- in combination with Zytiga for the treatment of Metastatic Castration-Resistant Prostate Cancer (mCRPC) in a phase II trial. -- and in a phase Ib/II study in combination with FOLFIRI and Avastin for second-line treatment of patients with metastatic colorectal cancer (mCRC) with a KRAS mutation.

6. DiaMedica Therapeutics Inc. (DMAC)

DiaMedica Therapeutics is a clinical-stage biopharmaceutical company developing novel treatments for kidney diseases and neurological disorders.

Gained 12.83% to close Thursday's trading at $2.55.

News: No news

Clinical Trials & Near-term Catalysts:

-- Enrollment and patient follow-up in a phase Ib clinical trial of DM199 in patients with moderate or severe Chronic Kidney Disease caused by Type I or Type II diabetes mellitus has been completed. The interim results have already been reported and they were positive. The full results of the study are expected to be provided in a peer-reviewed publication and/or poster presentation. -- A phase II, multiple cohort study of DM199 in IgA Nephropathy and Hypertensive African Americans with Chronic Kidney Disease is anticipated to start in the second half of 2019. -- A phase II study of DM199 for the treatment of Acute Ischemic Stroke, dubbed REMEDY, is ongoing. This study is expected to be completed in the fourth quarter of 2019 or first quarter of 2020.